Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
Thomas E. Hutson(Texas Oncology), Vladimir Lesovoy(Kharkiv Regional Clinical Psychiatric Hospital No 3), С Х Аль-Шукри(First Pavlov State Medical University of St. Petersburg), V.P. Stus(Regional Clinical Hospital named after II Mechnikov), Oleg Lipatov(Republican Oncological Clinical Dispensary), Angel H. Bair(Pfizer (United States)), Brad Rosbrook(Pfizer (United States)), Connie Chen(Pfizer (United States)), Sinil Kim(Pfizer (United States)), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada)
Cited by 405
Abstract
Related Papers
No related papers found
Powered by citation graph analysis